Results 221 to 230 of about 22,441 (303)

Has the time come to stop using control groups in trials of psychosocial interventions? [PDF]

World Psychiatry
Cuijpers P.
europepmc   +1 more source

Should Nonresponders Dictate the Use of Placebos?

, 2003
DeMarco, Joseph P.
core   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Unraveling the mystery of placebo effect in research and practice: An update. [PDF]

Perspect Clin Res
Mishra P, Bhargava S.
europepmc   +1 more source

Placebos in Clinical Care: For Whose Pleasure?

, 2003
Hill, Joal
core   +1 more source

Gabapentin as an add‐on analgesic to morphine in paediatric patients with chronic pain

British Journal of Clinical Pharmacology, EarlyView.
Aims Off‐label use of gabapentin for the treatment of chronic pain in children has increased over the last decade, with multiple clinical trials evaluating its role pain management and potential opioid‐sparing effects. To date, however, these studies appear to rely on empirical evidence without further consideration of pharmacokinetic‐pharmacodynamic ...
Paul Healy, Mariagrazia Felisi, Adriana Ceci, Oscar Della Pasqua, on Behalf of the GAPP Consortium, Corinne Alberti, Donato Bonifazi, Adriana Ceci, Thomas G. de Leeuw, Saskia N. de Wildt, Mariagrazia Felisi, Florentia Kaguelidou, Enora Le Roux, Rebecca Lundin, Laura Mangiarini, Dick Tibboel   +15 more
wiley   +1 more source

Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery. [PDF]

J Cataract Refract Surg
Levenson J, Walters TR, Martel J, Wang L, Nunez DJ.   +4 more
europepmc   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

The concept of placebo/nocebo response and effect. [PDF]

EULAR Rheumatol Open
Benedetti F.
europepmc   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source